Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深滬

已收盤 11-06 16:00:00 美东时间

14.84

-0.200

-1.33%

華盛通

立即下載

最高15.40
今開15.40
成交量 1.17万股
最低 14.56
昨收 15.04
總市值 5085.87万
52周最高 21.43
市盈率 ^靜 --
換手率 0.34%
52周最低 6.50
委比 -11.11%
總股本 342.71万
歷史最高 21.43
量比 0.61
振幅 5.59%
歷史最低 -1.5766
每手 1
風險率 4.11%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Fortress Biotech Inc.收涨0.54%，成交额23.96万美元

11月7日，Fortress Biotech Inc.（FBIO）收涨0.54%，报1.85美元，成交额23.96万美元，市值6145.53万美元。行情数据...

11-07 08:11
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026

Journey Medical Corporation will release its third quarter 2026 financial results after U.S. markets close on November 12, 2026. A conference call and audio webcast will be held at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international), or register online via the provided link. A live webcast will also be availa...

11-05 13:30
Fortress Biotech Inc.收跌4%，成交额37.31万美元

10月31日，Fortress Biotech Inc.（FBIO）收跌4%，报1.92美元，成交额37.31万美元，市值6403.34万美元。行情数据 •...

10-31 07:14
Fortress Biotech Inc.收涨2.04%，成交额36.4万美元

10月30日，Fortress Biotech Inc.（FBIO）收涨2.04%，报2美元，成交额36.4万美元，市值6670.15万美元。行情数据 • 开...

10-30 07:15
Fortress Biotech Inc.收涨2.58%，成交额36.21万美元

10月23日，Fortress Biotech Inc.（FBIO）收涨2.58%，报1.99美元，成交额36.21万美元，市值6636.8万美元。行情数据...

10-23 07:17
Fortress Biotech Inc.收跌2.09%，成交额49.62万美元

10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...

10-17 07:21
Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical Corporation (NASDAQ: DERM) announced that its CEO, Claude Maraoui, will attend two investor conferences in September 2026. The first is the Lake Street Capital Markets 10th Annual BIG10 Conference on September 10 in New York City, featuring 1x1 meetings. The second is the H.C. Wainwright 28th Annual Global Investment Conference on September 14, also in NYC, with a presentation and 1x1 meetings. A webcast of the H.C. Wainwright pre...

09-08 20:05
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...

08-19 20:05
Fortress Biotech Q2 Earnings Preview

Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+...

08-12 05:35
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad

Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the l...

07-27 20:03

派息除權日	每股總股息	派息日期
2024-06-14	0.20	2024-06-30
2024-05-14	0.20	2024-05-31
2024-04-12	0.20	2024-04-30
2024-03-14	0.20	2024-03-31
2024-02-14	0.20	2024-02-29
2024-01-11	0.20	2024-01-31
2023-12-14	0.20	2023-12-31
2023-11-14	0.20	2023-11-30
2023-10-12	0.20	2023-10-31
2023-09-14	0.20	2023-09-30
2023-08-14	0.20	2023-08-31
2023-07-13	0.20	2023-07-31
2023-06-14	0.20	2023-06-30
2023-05-12	0.20	2023-05-31
2023-04-13	0.20	2023-04-30
2023-03-14	0.20	2023-03-31
2023-02-14	0.20	2023-02-28
2023-01-12	0.20	2023-01-31
2022-12-14	0.20	2022-12-31
2022-11-14	0.20	2022-11-30
2022-10-13	0.20	2022-10-31
2022-09-14	0.20	2022-09-30
2022-08-12	0.20	2022-08-31
2022-07-14	0.20	2022-07-31
2022-06-14	0.20	2022-06-30
2022-05-12	0.20	2022-05-31
2022-04-13	0.20	2022-04-30
2022-03-14	0.20	2022-03-31
2022-02-14	0.20	2022-02-28
2022-01-13	0.20	2022-01-31
2021-12-14	0.20	2021-12-31
2021-11-12	0.20	2021-11-30
2021-10-14	0.20	2021-10-30
2021-09-14	0.20	2021-09-30
2021-08-12	0.20	2021-08-30
2021-07-14	0.20	2021-07-30
2021-06-14	0.20	2021-06-30
2021-05-13	0.20	2021-05-30
2021-04-14	0.20	2021-04-30
2021-03-12	0.20	2021-03-31
2021-02-11	0.20	2021-02-28
2021-01-14	0.20	2021-01-31
2020-12-14	0.20	2020-12-31
2020-11-12	0.20	2020-11-30
2020-10-14	0.20	2020-10-31
2020-09-14	0.20	2020-09-30
2020-08-20	0.20	2020-08-31
2020-07-17	0.20	2020-07-31
2020-06-12	0.59	2020-06-30
2020-03-13	0.59	2020-03-31
2019-12-12	0.59	2019-12-31
2019-09-12	0.59	2019-09-30
2019-06-13	0.59	2019-07-01
2019-03-14	0.59	2019-03-31
2018-12-13	0.59	2018-12-31
2018-09-13	0.59	2018-09-30
2018-06-14	0.59	2018-06-30
2018-03-14	0.59	2018-03-30

公司名稱	Fortress Biotech, Inc.
行業分類	Pharmaceuticals: Major
業務描述	Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深 滬

14.84

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP 深滬